

Examiner-Initiated Interview Summary	Application No.	Applicant(s)	
	09/653,267	EINI ET AL.	

Examiner
Mina Haghigatian

Art Unit
1616

All Participants:

Status of Application: _____

(1) Mina Haghigatian.

(3) _____.

(2) mary Rose Scozzafava.

(4) _____.

Date of Interview: 15 April 2005

Time: _____

Type of Interview:

Telephonic
 Video Conference
 Personal (Copy given to: Applicant Applicant's representative)

Exhibit Shown or Demonstrated: Yes No

If Yes, provide a brief description:

Part I.

Rejection(s) discussed:

Claims discussed:

120-121

Prior art documents discussed:

Part II.


SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

See Continuation Sheet

Part III.

It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.

It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.


SHELLEY A. DODSON
PRIMARY EXAMINER


(Examiner/SPE-Signature)

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: Applicant was contacted because in order to place the application in condition for allowance, it was determined that certain biologically active agents listed in claims 120 and 121, such as " a non-nucleoside reverse transcriptase inhibitor", " a nucleoside-analoog reverse transcriptase inhibitor" and "a protease inhibitor", were not enableed. Applicant agreed to delet said terms from the claims. .